cayston Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cayston, and when can generic versions of Cayston launch?
Cayston is a drug marketed by Gilead and is included in one NDA.
The generic ingredient in CAYSTON is aztreonam. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the aztreonam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cayston
A generic version of cayston was approved as aztreonam by FRESENIUS KABI USA on June 18th, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for cayston?
- What are the global sales for cayston?
- What is Average Wholesale Price for cayston?
Summary for cayston
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 73 |
Clinical Trials: | 6 |
Patent Applications: | 7,097 |
Drug Prices: | Drug price information for cayston |
What excipients (inactive ingredients) are in cayston? | cayston excipients list |
DailyMed Link: | cayston at DailyMed |
![cayston drug patent expirations Drug patent expirations by year for cayston](/p/graph/s/t/cayston-patent-expirations.png)
![Drug Prices for cayston](/p/graph/drug-price/cayston.png)
Recent Clinical Trials for cayston
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Dundee | Phase 2 |
Gilead Sciences | Phase 2 |
UCSF Benioff Children's Hospital Oakland | Phase 4 |
US Patents and Regulatory Information for cayston
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead | CAYSTON | aztreonam | FOR SOLUTION;INHALATION | 050814-001 | Feb 22, 2010 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for cayston
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Gilead | CAYSTON | aztreonam | FOR SOLUTION;INHALATION | 050814-001 | Feb 22, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Gilead | CAYSTON | aztreonam | FOR SOLUTION;INHALATION | 050814-001 | Feb 22, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Gilead | CAYSTON | aztreonam | FOR SOLUTION;INHALATION | 050814-001 | Feb 22, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Gilead | CAYSTON | aztreonam | FOR SOLUTION;INHALATION | 050814-001 | Feb 22, 2010 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for cayston
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Gilead Sciences Ireland UC | Cayston | aztreonam | EMEA/H/C/000996 Cayston is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.Consideration should be given to official guidance on the appropriate use of antibacterial agents. |
Authorised | no | no | no | 2009-09-21 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for cayston
See the table below for patents covering cayston around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 2360692 | ⤷ Sign Up | |
Luxembourg | 91851 | ⤷ Sign Up | |
Australia | 2009233632 | ⤷ Sign Up | |
Denmark | 2158901 | ⤷ Sign Up | |
Austria | 502623 | ⤷ Sign Up | |
Portugal | 1641436 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for cayston
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1353647 | SPC/GB11/049 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: AZTREONAM LYSINE; REGISTERED: UK EU/1/09/543/001 20090921 |
1353647 | 91851 | Luxembourg | ⤷ Sign Up | 91851, EXPIRES: 20240921 |
1353647 | 2011C/029 | Belgium | ⤷ Sign Up | PRODUCT NAME: AZTREONAM LYSINE; AUTHORISATION NUMBER AND DATE: EU/1/09/543/001 20090923 |
2158901 | 2018C/001 | Belgium | ⤷ Sign Up | PRODUCT NAME: CAYSTON - AZTREONAM; AUTHORISATION NUMBER AND DATE: EU/1/09/543/001 20090923 |
2158901 | 122018000044 | Germany | ⤷ Sign Up | PRODUCT NAME: AZTREONAMIYSIN; REGISTRATION NO/DATE: EU/1/09/543/001 20090921 |
1353647 | 1190027-1 | Sweden | ⤷ Sign Up | MARKETING AUTHORIZATION NUMBER AND DATE OF GRANT/NOTIFICATION: EU/1/09/543/001, 2009-09-23; PERIOD OF VALIDITY (FROM - UNTIL): 2021-12-21 - 2024-09- 22 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |